External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

WCGC 2021

-
Coming soon
02:32 PM
Duration 10mins Virtual
5-FU/LV + cetuximab + vemurafenib as maintenance therapy for BRAF-mutant (BRAF mut ) metastatic colorectal cancer (mCRC): Efficacy, safety and exploratory biomarker findings from Cohort 1 of the MODUL trial
Ducreux M, Tabernero J, Arnold D, O’Dwyer P, Perdicchio M, Assaf ZJ, Das Thakur M, Irahara N, Tahiri A, Schmoll H-J, Van Cutsem E, de Gramont A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
01:39 PM
Duration 12mins Virtual
Phase Ib study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab▼ in patients with metastatic esophageal cancer
Wainberg Z, Matos I, Delord J-P, Cassier P, Gil M, Kim T, LoRusso P, Bahleda R, Italiano A, Mendus D, Hoang T, Xue C, Wen P, Carvalho O, Pham T, Patil NS, Meng R, Bendell J, Cervantes A, Cho BC

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar